Novel vaccine therapy for Alzheimer's disease - Recent progress and our approach

Brain and Nerve

Volumn 60, Issue 8, 2008, Pages 931-940

  Okura, Yoshio ^a   Matsumoto, Yoh ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

A reduction; Alzheimer's disease; Microglial activation; Nonviral DNA vaccine; Phagocytosis by microglia

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETABLOC; DNA VACCINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; DEMENTIA; DNA IMMUNIZATION; HUMAN; HUMAN CELL; MENINGOENCEPHALITIS; MICROGLIA; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PHAGOCYTOSIS; REVIEW; VACCINATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; PEPTIDE FRAGMENTS; VACCINES, DNA;

EID: 51149117545     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Citron M: Alzheimer's disease: treatments in discovery and development. Nat Neurosci 5 Suppl: 1055-1057, 2002
2. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388, 1991
3. Schenk D, Barbour R, Dunn W, Gordon. G, Grajeda H, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177, 1999
4. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, et al: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408: 982-985, 2000
5. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982, 2000,
6. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, et al: Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8: 1270-1275, 2002
7. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, et al: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61: 46-54, 2003
8. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452, 2003
9. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562, 2005
10. Maier M, Seabrook TJ, Lemere CA: Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. Neurodegener Dis 2: 267-272, 2005
11. Masters CL, Beyreuther K: Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain 129: 2823-2839, 2006
12. Maier M, Seabrook TJ, Lazo ND, Jiang L, Das P, et al: Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 26: 4717-4728, 2006
13. Frenkel D, Maron R, Burt DS, Weiner HL: Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 115: 2423-2433, 2005
14. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919, 2000
15. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98: 8850-8855, 2001
16. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, et al: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298: 1379, 2002
17. Tang DC, DeVit M, Johnston SA: Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154, 1992
18. Barry MA, Lai WC, Johnston SA: Protection against mycoplasma infection using expression-library immunization, Nature 377: 632-635, 1995
19. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749, 1993
20. Hoffman SL, Doolan DL, Sedegah M, Gramzinski R, Wang H, et al: Nucleic acid malaria vaccines. Current status and potential. Ann N Y Acad Sci 772: 88-94, 1995
21. Kim HD, Maxwell JA, Kong FK, Tang DC, Fukuchi K: Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. Biochem Biophys Res Commun 336: 84-92, 2005
22. Zhang J, Wu X, Qin C, Qi J, Ma S, et al: A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol Dis 14: 365-379, 2003
23. Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, et al: Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheimer Dis 6: 483-488, 2004
24. Marshall E: Gene therapy. Second child in French trial is found to have leukemia. Science 299: 320, 2003
25. Check E: Gene therapy put on hold as third child develops cancer. Nature 433: 561, 2005
26. Urabe M, Ding C, Kotin RM: Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13: 1935-1943, 2002
27. Nishikawa M, Huang L: Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther 12: 861-870, 2001
28. Nishikawa M, Hashida M: Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol Pharm Bull 25: 275-283, 2002
29. Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babikyan D, et al: Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol 33: 3232-3241, 2003
30. Schiltz JG, Salzer U, Mohajeri MH, Franke D, Heinrich J, et al: Antibodies from a DNA peptide vaccination decrease the amyloid burden in a mouse model of Alzheimer's disease. J Mol Med 82: 706-714, 2004
31. Matsumoto Y, Jee Y, Sugisaki M: Successful TCR-based immunotherapy for autoimmune myocarditis with DNA vaccines after rapid identification of pathogenic TCR. J Immunol 164: 2248-2254, 2000
32. Okura Y, Miyakoshi A, Kohyama K, Park IK, Staufenbiel M, et al: Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc Natl Acad Sci U S A 103: 9619-9624, 2006
33. Marshall E: Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245, 1999
34. Check E: A tragic setback. Nature 420: 116-118, 2002
35. Kay MA: AAV vectors and tumorigenicity. Nat Biotechnol 25: 1111-1113, 2007
36. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, et al: AAV vector integration sites in mouse hepatocellular carcinoma. Science 317: 477, 2007
37. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, et al: Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 43: 258-272, 2000
38. Bard F, Barbour R, Cannon C, Carretto R, Fox M, et al: Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 100: 2023-2028, 2003
39. Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, et al: Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 15: 11-20, 2004
40. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 22: 7873-7878, 2002
41. Solomon B, Koppel R, Frankel D, Hanan-Aharon E: Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A 94: 4109-4112, 1997
42. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457, 2002
43. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM: Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295: 2264-2267, 2002
44. O'Toole M, Janszen DB, Slonim DK, Reddy PS, Ellis DK, et al: Risk factors associated with beta-amyloid(1-42) immunotherapy in preimmunization gene expression patterns of blood cells. Arch Neurol 62: 1531-1536, 2005
45. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 298: 789-791, 2002
46. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, et al: Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22: 6331-6335, 2002